<p>BDR Pharmaceuticals on Wednesday said it has launched the generic version of Lenvatinib drug for the treatment of various types of cancers in India.</p>.<p>The generic version of the drug has been launched under the brand name 'Bdfoie' in the country.</p>.<p>The capsules are used for the treatment of differentiated thyroid cancer, advanced liver cancer and advanced kidney cancer, BDR Pharma said in a statement.</p>.<p>The results of clinical trials showed encouraging results with safety and efficacy on patients with aggressive tumours, it added.</p>.<p>The drug is priced at Rs 1,620 (4 mg) and Rs 2,970 (10 mg) for a pack of 10 capsules, the statement said.</p>.<p>"By launching cost-effective therapy options we want to mitigate the challenges faced by Indian patients in seeking access to treatment and finding a timely cure for life threatening diseases," BDR Pharmaceuticals CMD Dharmesh Shah said. </p>
<p>BDR Pharmaceuticals on Wednesday said it has launched the generic version of Lenvatinib drug for the treatment of various types of cancers in India.</p>.<p>The generic version of the drug has been launched under the brand name 'Bdfoie' in the country.</p>.<p>The capsules are used for the treatment of differentiated thyroid cancer, advanced liver cancer and advanced kidney cancer, BDR Pharma said in a statement.</p>.<p>The results of clinical trials showed encouraging results with safety and efficacy on patients with aggressive tumours, it added.</p>.<p>The drug is priced at Rs 1,620 (4 mg) and Rs 2,970 (10 mg) for a pack of 10 capsules, the statement said.</p>.<p>"By launching cost-effective therapy options we want to mitigate the challenges faced by Indian patients in seeking access to treatment and finding a timely cure for life threatening diseases," BDR Pharmaceuticals CMD Dharmesh Shah said. </p>